Is CJC-1295 an approved medicine?

No. It has not been approved by any regulator. We supply it as a research chemical for laboratory use only.

What is the difference between CJC-1295 with and without DAC?

The with-DAC form binds blood albumin and lasts for days, and it is the form the human trials tested. The without-DAC form (modified GRF 1-29) is a different, short-acting molecule; its long-duration claims are not established. They should not be treated as the same thing.

What has CJC-1295 research looked at?

Early human trials of the with-DAC form that measured GH, IGF-1, pulsatility and half-life, plus animal work. The cited studies are above.

CJC-1295 research: what the studies have looked at

This page summarises the published research on CJC-1295, for reference. It states what each study investigated and in what model, not an effect in people, and it is not medical advice. CJC-1295 is not an approved medicine; what we supply is a research chemical for laboratory use only.

What CJC-1295 is, and a naming point

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). There is a distinction worth getting right before the studies. The form the human trials used carries a "drug affinity complex" (DAC) that binds it to blood albumin so it lasts for days, and it is that "with DAC" form the papers below tested. A second form sold in the research-chemical market, "without DAC" (often called modified GRF 1-29), is a different, short-acting molecule whose long-duration claims are not established in the literature. Neither is an approved drug.

What the studies investigated

Teichman et al. (2006), Journal of Clinical Endocrinology and Metabolism 91(3):799-805. Human, phase-1, healthy adults. Investigated CJC-1295 with DAC and reported dose-dependent rises in GH and IGF-1 over days, with a half-life of about 6 to 8 days Source.

Ionescu and Frohman (2006), Journal of Clinical Endocrinology and Metabolism 91(12):4792-4797. Human. Investigated the with-DAC form and reported that GH secretion stayed pulsatile while total output rose Source.

Alba et al. (2006), American Journal of Physiology-Endocrinology and Metabolism 291(6):E1290-E1294. GHRH-knockout mice. Investigated CJC-1295 with DAC in a model lacking endogenous GHRH Source.

Mechanism, as described in the literature

As a GHRH analogue it is described as prompting the pituitary to release growth hormone, which raises IGF-1; the DAC version binds albumin, which is what extends its action from minutes to days. The human work above measured GH and IGF-1 levels, pulsatility and pharmacokinetics over fixed windows, not clinical outcomes, and it was done under supervision in small groups. The without-DAC form was not what those trials tested.

The material we supply

We supply CJC-1295 as a research chemical, released against a written specification with a batch certificate of analysis. It is not a medicine and is not for human or animal use. For the vial sizes, the price per mg and how to order, see the CJC-1295 compound page; the COA lookup pulls the certificate for any batch. The references above link to each study’s record; this summary is for research and educational reference only.